Eyeseryl

What is Eyeseryl?

Eyeseryl (INCI name Acetyl Tetrapeptide-5) is a cosmetic tetrapeptide marketed for under-eye puffiness, periorbital edema, and dark circles, developed by Lipotec S.A. (now part of Lubrizol Life Science Beauty) and sold as a cosmetic-ingredient INCI label for inclusion in finished topical eye-care formulations. The marketing positioning frames Eyeseryl as a multi-mechanism eye-area cosmetic active addressing three principal contributors to under-eye appearance: periorbital edema (through proposed effects on capillary permeability and lymphatic drainage), glycation-related discoloration (through proposed anti-glycation activity reducing AGE accumulation in the thin periorbital skin), and skin elasticity (through general cosmetic-peptide signaling effects). The peer-reviewed clinical evidence base for Eyeseryl is essentially absent in PubMed-indexed literature — the product is supported predominantly by Lipotec/Lubrizol in-house formulation studies, cosmetic-industry evaluation reports, and finished-product testimonial data rather than independently published controlled trials. This is the standard evidence pattern for cosmetic-active INCI ingredients sold as components of finished eye-care products rather than as drug-approved therapeutics. Eyeseryl is widely used in commercial under-eye creams and serums across the premium, mid-tier, and mass-market cosmetic landscape, frequently combined with other eye-area cosmetic actives (caffeine for vasoconstriction-related puffiness reduction, hyaluronic acid for hydration, copper peptides like GHK-Cu, vitamin K for capillary support, and various brightening agents for dark-circle appearance). The cosmetic positioning is appropriate; the more substantial 'reverses dark circles' or 'eliminates puffiness' marketing claims typical of consumer marketing exceed what the available evidence can support. Anyone considering Eyeseryl-containing products should engage with the honest framing — a cosmetic-peptide INCI ingredient with mechanism plausibility but limited independent clinical evidence, appropriate as a cosmetic adjunct alongside foundational eye-area care (sunscreen, adequate sleep, allergy management, hydration) but not as a substitute for clinical evaluation when significant periorbital concerns warrant medical attention.

What Eyeseryl Is Investigated For

Eyeseryl is a cosmetic-peptide INCI ingredient sold as a component of finished eye-area topical products. The Lipotec/Lubrizol marketing positioning frames it as a multi-mechanism active addressing periorbital edema (capillary permeability, lymphatic drainage), glycation-related discoloration (AGE reduction in thin periorbital skin), and elasticity. The peer-reviewed clinical evidence base is essentially absent in PubMed-indexed literature, which is the standard pattern for cosmetic-active INCI ingredients — the evidence comes from in-house formulation studies and cosmetic-industry evaluation rather than independently published trials. Effect sizes in cosmetic-grade testing are typically modest, on surrogate appearance endpoints over 4-12 weeks of regimen use. The 'reverses dark circles' and 'eliminates puffiness' marketing claims that characterize consumer-facing presentation substantially exceed what the available evidence supports. As a cosmetic adjunct alongside foundational eye-area care (sunscreen, sleep, allergy management, hydration, evidence-based actives like topical retinoids and vitamin C), Eyeseryl-containing products are reasonable to try without high expectations. As a substitute for clinical evaluation when significant or persistent periorbital concerns warrant medical attention (allergic shiners, structural dark circles, post-surgical edema, etc.), it is not appropriate.

How It Works

Eyeseryl is a small cosmetic peptide marketed for under-eye puffiness and dark circles. The marketing claims are that it reduces fluid retention around the eyes (by helping capillaries hold fluid better) and reduces dark-circle appearance (by reducing glycation, which is when sugars stick to proteins and discolor them in aging skin). The evidence is mostly from the manufacturer's own studies — there's not much independent peer-reviewed work. Effect sizes are probably modest. It's a reasonable cosmetic adjunct ingredient to find in an eye cream alongside other actives like caffeine and hyaluronic acid, but the bigger wins for under-eye appearance come from sleep, sun protection, and (for structural concerns) procedural interventions.

Eyeseryl is a four-residue cosmetic peptide with a fully disclosed, CAS-registered structure: N-acetyl-β-alanyl-L-histidyl-L-seryl-L-histidine (Ac-β-Ala-His-Ser-His, CAS 820959-17-9, C20H28N8O7, molecular weight 492.5), developed by Lipotec S.A. and sold as a cosmetic-active INCI ingredient. The first two residues are the interesting part: Ac-β-Ala-His is acetylated carnosine, the endogenous dipeptide best known for anti-glycation and carbonyl scavenging, extended here by Ser-His. That structural lineage is the most coherent mechanistic rationale the molecule has — and it is an argument by analogy, not a demonstrated property of the tetrapeptide. The mechanism the manufacturer actually claims is angiotensin-converting enzyme (ACE) inhibition, producing a draining and decongestant effect around the eye. Two peer-reviewed reviews repeat it, but both trace back to manufacturer literature rather than primary data, and the only experimental measurement anywhere in the indexed literature is an in vitro screen: Wu and colleagues (2021) selected 100 μg/mL as the optimal concentration of acetyl tetrapeptide-5 for angiotensin-converting enzyme 1 activity. There is no published inhibition constant, no dose-response curve, and no demonstration that ACE inhibition occurs at the concentrations actually present in a finished eye cream. The secondary claims are weaker still: the anti-glycation claim has no peer-reviewed source at all and rests on supplier copy plus the carnosine analogy, and the capillary-permeability framing common in consumer marketing is not attributable to any published study of this peptide. Claims that Eyeseryl inhibits carbonic anhydrase circulate online and have no source whatsoever. The mechanistic case is at the cosmetic-grade level rather than the molecular-biology rigorous level. The capillary-permeability and anti-glycation claims have not been characterized at receptor-level resolution and are based on Lipotec/Lubrizol formulation testing using surrogate endpoints. The general cosmetic-peptide signaling framework that underlies many INCI peptide ingredients (matrikine, signal peptide, carrier peptide concepts) applies in a broad way to Eyeseryl but does not produce specific mechanism-of-action evidence comparable to well-characterized matrikines like Matrixyl or to copper peptides like GHK-Cu. The formulation context matters substantially. Use levels are widely misreported. Eyeseryl is sold as a solution containing 0.1% acetyl tetrapeptide-5, and that solution is recommended at 1-10% of a formula — so the peptide itself ends up at roughly 0.001-0.01%, or 10-100 ppm, in a finished eye cream, two to three orders of magnitude below the “1-3%” figure usually quoted. The manufacturer's own efficacy work was run at 1% of the solution, about 10 ppm of peptide. Eyeseryl is typically combined with caffeine, often combined with caffeine (vasoconstriction for acute puffiness), hyaluronic acid (hydration), other peptides (palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, GHK-Cu), brightening agents (kojic acid, alpha arbutin, tranexamic acid for dark-circle appearance), and antioxidants. The finished-product evidence comes from cosmetic-industry trials rather than independent peer-reviewed work, and effect sizes on appearance endpoints are typically modest over 4-12 weeks of regimen use.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Eyeseryl:

• 01Independent peer-reviewed clinical trials of Eyeseryl specifically — the existing evidence base is predominantly cosmetic-industry in-house studies
• 02Mechanism characterization at the molecular biology level — the capillary-permeability and anti-glycation claims have not been validated at receptor-level resolution
• 03Long-term safety profile of chronic periorbital cosmetic-peptide application
• 04Comparative effectiveness studies of Eyeseryl-containing finished products vs alternative cosmetic-active eye-area formulations (caffeine-only, copper-peptide-based, retinol-based)

Forms & Administration

Eyeseryl is sold exclusively as an INCI ingredient in finished topical cosmetic products — under-eye creams, gels, and serums marketed for periorbital appearance. Concentration is widely misreported: the trade material is a solution containing 0.1% acetyl tetrapeptide-5, used at 1-10% of a formula, so the peptide itself is present at roughly 10-100 ppm (0.001-0.01%) in a finished product. Application is generally morning and/or evening to clean periorbital skin. The peptide is not sold as a stand-alone consumer product or as an injectable.

Common Questions

Who Eyeseryl Is NOT For

Drug & Supplement Interactions

There are no known clinically significant drug interactions for topical cosmetic Eyeseryl. The peptide is applied topically with minimal systemic absorption, and interactions with oral or systemic medications are not established. In multi-active eye-area formulations, Eyeseryl is generally compatible with other cosmetic ingredients (caffeine, hyaluronic acid, other peptides, antioxidants) but may interact unpredictably with strong actives (high-strength retinoids, vitamin C at low pH) — reducing concentration or alternating application time can mitigate any irritation.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions